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Abstract
A strain of Escherichia coli was positive for 5 aminoglycoside
modifying enzyme genes (aac(3)-I, aac(6¢)-Ib-cr, ant(3¢¢¢¢)-I,
aadA5, and aph(3¢)-I) in PCR assays. And these positive genes
confer resistance to aminoglycosides (gentamicin and tobramycin).
This is the ﬁrst report of emergence of ﬁve kinds of aminoglyco-
side-modifying enzymes genes simultaneously in E. coli worldwide.
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A 31-year-old male patient suffering from a urinary tract
infection was admitted to The First Afﬁliated Hospital of
Nanjing Medical University in Nanjing, China, on 5 August
2006. A strain of Escherichia coli was isolated from the urine.
The patient was treated with moxiﬂoxacin, and was healed
and discharged from hospital on 17 August 2006.
The isolate was identiﬁed with Vitek Gram-negative identi-
ﬁcation cards (bioMe´rieux-Vitek, Hazelwood, MO, USA), and
the antimicrobial susceptibility proﬁle was determined with
the disk diffusion and agar dilution methods according to the
CLSI. Modiﬁed three-dimensional tests were performed to
conﬁrm an extended-spectrum b-lactamase, and not an
AmpC, phenotype, with the CLSI method [1]. Whole cell
DNA from the strain of E. coli, prepared by proteinase K
digestion, was used as a template in PCR assays. PCR was
performed with the primers (Wuxi Clone Gen-Tech Insti-
tute, Wuxi, Jiangsu, China) for 14 aminoglycoside-modifying
enzyme genes (aac(3)-I, aac(3)-II, aac(3)-III, aac(3)-IV, aac(6¢)-
Ib, aac(6¢)-II, ant(2¢¢)-I, ant(3¢¢)-I, aadA4/5, aadA6/16, ant(4¢)-I,
aph(3¢)-I, aph(3¢)-IIa, and aph(3¢)-IIb) and six 16S rRNA meth-
ylase genes (armA, rmtA, rmtB, rmtC, rmtD, and npmA),
which were designed on the basis of genotypes published in
GenBank. PCR conditions were: 2 min at 93C; 35 cycles of
30 s at 93C, 30 s at 55C, and 1 min at 72C; and, ﬁnally,
5 min at 72C. Positive and negative controls were per-
formed in every PCR assay. The amplicons were puriﬁed
with PCR Kits (Wuxi Clone Gen-Tech Institute), and were
subsequently sequenced on an ABI PRISM377 sequencer ana-
lyser (Applied Biosystems, Foster City, CA, USA).
According to antibiotic susceptibility testing with disk dif-
fusion methods and agar dilution methods, the E. coli strain
was susceptible to amikacin, but resistant to gentamicin and
tobramycin (Table 1).
Moreover, the E. coli strain was deﬁned as a multidrug-
resistant strain, as it was resistant to three or more unique
antimicrobial classes. According to antibiotic susceptibility
testing with disk diffusion methods, the E. coli strain was
resistant to b-lactams, including cefuroxime, cefazolin, cefe-
pime, cefotaxime, ceftazidime, and aztreonam, and it was
resistant to quinolones, including ciproﬂoxacin and levoﬂoxa-
cin; it was also resistant to sulphamethoxazole–trimethoprim.
Aminoglycoside-modifying enzymes catalyse the covalent
modiﬁcation of speciﬁc amino or hydroxyl functions, leading
to a chemically modiﬁed drug that binds poorly to ribosomes
and for which the energy-dependent phase II of accelerated
drug uptake also fails to occur, thereby resulting most often
in high-level resistance. The enzymes modifying aminoglyco-
sides are N-acetyltransferases (AACs), which use acetyl-
coenzyme A as the donor and affect amino functions, and O-
nucleotidyltransferases (ANTs) and O-phosphotransferases
(APHs), which both use ATP as the donor and affect hydro-
xyl functions [2]. The E. coli strain was positive for aac(3)-I,
aac(6¢)-Ib, ant(3¢¢)-I, aadA4/5 and aph(3¢)-I in PCR assays.
However, it was negative for the other nine aminoglycoside-
modifying enzyme genes. The presence of aac(6¢)-Ib, con-
ﬁrmed as aac(6¢)-I b-cr, and the presence of aadA4/5, con-
ﬁrmed as aadA5, were determined by sequencing and
BLASTn algorithm. The aac(3)-I gene encodes aminoglycoside
3-N-acetyltransferase, the ant(3¢¢)-I gene encodes amino-
glycoside 3¢¢-O-nucleotidyltransferase, the aph(3¢)-I gene
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encodes aminoglycoside 3-O-phosphotransferase, and the
aadA5 gene encodes aminoglycoside 3¢¢-adenyltransferease,
so these four genes confer resistance to aminoglycosides.
Moreover, the aac(6¢)-Ib-cr genes encodes aminoglycoside
N-acetyltransferase and confers resistance against aminogly-
cosides as well as ﬂuoroquinolones simultaneously [3]. This
is the ﬁrst report of the emergence of ﬁve aminoglycoside-
modifying enzyme genes simultaneously in E. coli worldwide.
Sequencing of the whole genome of this strain is needed to
better understand how this strain has accumulated these
resistance-encoding genes.
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TABLE 1. Antimicrobial susceptibilities of a strain of multidrug-resistant Escherichia coli related to aminoglysoside resistance
linked to the genes detected
Antimicrobial agent Disk diffusion (mm) Agar dilution (mg/L) Laboratory report Genes detected
Gentamicin 7 128 R aac(3)-I, ant(3¢¢)-I, aph(3¢)-I, aadA5, aac(6¢)-Ib-cr
Tobramycin 7 R
Amikacin 19 8 S
R, resistant; S, sensitive.
E12 Clinical Microbiology and Infection, Volume 18 Number 1, January 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E11–E12
